Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.31 |
| ▸ | CBFB | Q13951 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923923 | 0.95 | EGFR (0.34) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL427425 | 0.86 | — | — | |
| SCHEMBL1191143 | 0.77 | BRD4 (0.34) | BRD4ALDH1A1HPGDRUNX1CBFB | |
| SCHEMBL12871708 | 0.74 | ELANE (0.36) | BRD4KDM4EALDH1A1MAPTGAA | |
| SCHEMBL10881461 | 0.73 | ALDH1A1 (0.32) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL19846937 | 0.73 | TP53 (0.31) | BRD4KDM4EALDH1A1MAPTGAA | |
| SCHEMBL7932132 | 0.72 | BRD4 (0.31) | BRD4 | |
| SCHEMBL12871718 | 0.70 | — | — | |
| SCHEMBL6086232 | 0.70 | ELANE (0.32) | — | |
| SCHEMBL1177014 | 0.68 | HSD17B10 (0.34) | KDM4EALDH1A1MAPTHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428423-B2 | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2025-09-30 | — | — | US | disclosed |
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-3608321-B1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) | 2022-09-07 | — | — | EP | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-9487474-B2 | Imino compounds as protecting agents against ultraviolet radiations | Elkimia, Inc. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9487474-B2 | Imino compounds as protecting agents against ultraviolet radiations | Elkimia, Inc. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-20150152046-A1 | IMINO COMPOUNDS AS PROTECTING AGENTS AGAINTS ULTRAVIOLET RADIATIONS | ELKIMIA (CA) | 2015-06-04 | — | — | US | disclosed |
| US-20150152046-A1 | IMINO COMPOUNDS AS PROTECTING AGENTS AGAINTS ULTRAVIOLET RADIATIONS | ELKIMIA (CA) | 2015-06-04 | — | — | US | disclosed |
| US-8399444-B2 | Bicyclic imidazole as DP1 receptor antagonists | GlaxoSmithKline Intellectual Property Development Ltd. (GB) | 2013-03-19 | — | — | US | disclosed |
| WO-2010070021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | WO | disclosed |
| US-20080293972-A1 | Process for Preparing Substituted Anisidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293972-A1 | Process for Preparing Substituted Anisidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
| WO-2007053755-A1 | PROCESS FOR PREPARING SUBSTITUTED ANISIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | WO | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-0082599-B1 | M-HYDROXYPHENYL SUBSTITUTED COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1986-01-15 | — | — | EP | disclosed |
| US-4463177-A | Process for making m-hydroxyphenyl substituted compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1984-07-31 | — | — | US | disclosed |
| EP-0082599-A1 | m-Hydroxyphenyl substituted compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | CDK4, CDK2, CDKL1 | BRD4 171/4885KDM4E 784/4885ALDH1A1 2840/4885 |
| US-20150152046-A1 | IMINO COMPOUNDS AS PROTECTING AGENTS AGAINTS ULTRAVIOLET RADIATIONS | ERCC4, ERCC1, RAD51 | BRD4 2610/4885KDM4E 3747/4885ALDH1A1 260/4885 |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | BRD4 1055/4885KDM4E 2551/4885ALDH1A1 3370/4885 |
| US-12428423-B2 | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor | CDK4, CDK2, CDKL1 | BRD4 171/4885KDM4E 784/4885ALDH1A1 2840/4885 |
| US-20080293972-A1 | Process for Preparing Substituted Anisidines | ALKBH3, ALKBH1, ALK | BRD4 4284/4885KDM4E 676/4885ALDH1A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.